Pre- treatment protein landscape in HER2-negative breast cancer treated with carboplatin in a neoadjuvant chemotherapy setting

被引：0
|
作者：
Dahle, Maria Aanesland
Egeland, Eivind Valen
Prasmickaite, Lina
Lingjaerde, Ole Christian
Russnes, Hege
Garred, Oystein
Smebye, Marianne L.
Skjerven, Helle
Schlichting, Ellen
Naume, Bjorn
Maelandsmo, Gunhild
Engebraaten, Olav
Haugen, Mads H.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-2170
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2170
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The addition of bevacizumab to neoadjuvant chemotherapy in HER2-negative inflammatory breast cancer, more not necessarily better
    Al-Shamsi, Humaid O.
    Ibrahim, Nuhad K.
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S694 - S696
  • [22] Immune function and response to neoadjuvant chemotherapy in hormone receptor positive, HER2-negative breast cancer
    Matikas, A.
    Lovrot, J.
    Ramberg, A.
    Eriksson, M.
    Lindsten, T.
    Lekberg, T.
    Hedenfalk, I.
    Loman, N.
    Bergh, J.
    Erlandsson, A.
    Hatschek, T.
    Foukakis, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [23] Secreted Protein Acidic and Rich in Cysteine (SPARC) Polymorphisms in Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer Patients
    Arqueros, Cristina
    Salazar, Juliana
    Gallardo, Alberto
    Andres, Marta
    Tibau, Ariadna
    Bell, Olga Lidia
    Artigas, Alicia
    Lasa, Adriana
    Cajal, Teresa
    Lerma, Enrique
    Barnadas, Agusti
    BIOMEDICINES, 2023, 11 (12)
  • [24] Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer
    Matsuda, Naoko
    Wang, Xiaoping
    Lim, Bora
    Krishnamurthy, Savitri
    Alvarez, Ricardo H.
    Willey, Jie S.
    Parker, Charla A.
    Song, Juhee
    Shen, Yu
    Hu, Jianhua
    Wu, Wenhui
    Li, Nan
    Babiera, Gildy V.
    Murray, James L.
    Arun, Banu K.
    Brewster, Abenaa M.
    Reuben, James M.
    Stauder, Michael C.
    Barnett, Chad M.
    Woodward, Wendy A.
    Le-Petross, H. T. Carisa
    Lucci, Anthony
    DeSnyder, Sarah M.
    Tripathy, Debu
    Valero, Vicente
    Ueno, Naoto T.
    JAMA ONCOLOGY, 2018, 4 (09) : 1207 - 1213
  • [25] Endo Predict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
    Bertucci, Francois
    Finetti, Pascal
    Viens, Patrice
    Birnbaum, Daniel
    CANCER LETTERS, 2014, 355 (01) : 70 - 75
  • [26] Efficacy of adjuvant 5-Fluorouracil in residual HER2-negative breast cancer following neoadjuvant chemotherapy
    Owusu-Brackett, N.
    Scott, S.
    Yuca, E.
    Evans, K. W.
    Tapia, C.
    Meric-Bernstam, F.
    CANCER RESEARCH, 2019, 79 (04)
  • [27] Predictive value of serum thymidine kinase 1 during neoadjuvant chemotherapy in HER2-negative breast cancer
    Zhao, X.
    Tang, Q.
    Li, H.
    Zhou, X.
    Li, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S1408 - S1408
  • [28] Efficacy and safety of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy in HER2-negative breast cancer
    Yang, Miaomiao
    Qu, Huajun
    Liu, Aina
    Liu, Jiannan
    Sun, Ping
    Li, Hua
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (07) : 1561 - 1566
  • [29] A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients
    Haeberle, L.
    Erber, R.
    Gass, P.
    Hein, A.
    Jud, S. M.
    Langemann, H.
    Rauh, C.
    Hack, C. C.
    Schulz-Wendtland, R.
    Hartmann, A.
    Beckmann, M. W.
    Lux, M. P.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [30] Patient perspective on sequence order of anthracyclines and taxanes in neoadjuvant chemotherapy in HER2-negative breast cancer patients
    Altundag, Kadri
    JOURNAL OF BUON, 2021, 26 (03): : 1169 - 1169
12345